Finance
AstraZeneca buys drugmaker Caelum in deal worth up to $500 mln
Above Article Content Ad
Sept 29 (Reuters) – AstraZeneca stated on Wednesday its newly acquired Alexion division will buy the remaining fairness in drugmaker Caelum Biosciences in a deal that may very well be price as much as $500 million, increasing its entry into rare-disease remedies.
The Anglo-Swedish drugmaker stated it will take ahead Caelum’s late-stage trial of a possible drugs to deal with AL amyloidosis, a uncommon illness that impacts the center, kidneys and different organs.
Reporting by Yadarisa Shabong in Bengaluru; Enhancing by Sherry Jacob-Phillips
: